To use all functions of this page, please activate cookies in your browser.
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
6 Current white paper of Frost & Sullivan
rssFrost & Sullivan interview with Mr. Steve Fishwick, AstraZeneca
06-28-2006
Aparna Singh (AS), Program Manager for the Chemicals Materials and Foods team at Frost & Sullivan India, recently caught up with Mr. Steve Fishwick (SF), Projects Group Director, AstraZeneca at the Frost & Sullivan’s Global Life Sciences Summit 2006 at Goa, India. He was one of the key ...
Frost & Sullivan interview with Dr. Michael Kolb, Wyeth
06-27-2006
Aparna Singh (AS), Program Manager with Frost & Sullivan’s Chemical Materials and Foods team caught up with Dr. Michael Kolb (Dr. MK) at Frost & Sullivan’s Opportunities in Lifescience Molecules: Global Partnership Summit 2006. This annual summit was held at Goa (India) from 21st -23rd May, ...
10-31-2005
Looking at the increasing trend towards partnerships and alliances in the pharmaceutical industry, Frost & Sullivan had organized a premium conference, “Global PharmAlliance 2005 – Becoming the partner of choice” in Mumbai (India). The two day event focused on giving an insight into the world ...
10-26-2005
IntroductionPharmaceutical industry is constantly undergoing a change. In the past pharmaceuticals had a different strategy, companies use to build all the products internally and confine access to information or resources to third parties. The past situation is changing; in-house resources ...
09-19-2005
Introduction New pharmaceutical strategies pursue increased Research and Development (R&D) investments ranging 15-20% in contrast to late 80’s period where classical model across was 10%. The annual budget allocation spent with clinical research organizations (CRO) is approximately $12 ...
09-01-2005
The Big Hunt Alliances have evolved into a critical cornerstone of R&D strategy in the global pharmaceutical industry. No other industry has been leveraging this business model as successfully as the global pharmaceutical industry in its drive for innovation and success. Over three thousand ...





